Production of a Human Metabolite of Atorvastatin by Bacterial CYP102A1 Peroxygenase
Open Access
- 10 January 2021
- journal article
- research article
- Published by MDPI AG in Applied Sciences
- Vol. 11 (2) , 603
Abstract
Atorvastatin is a widely used statin drug that prevents cardiovascular disease and treats hyperlipidemia. The major metabolites in humans are 2-OH and 4-OH atorvastatin, which are active metabolites known to show highly inhibiting effects on 3-hydroxy-3-methylglutaryl-CoA reductase activity. Producing the hydroxylated metabolites by biocatalysts using enzymes and whole-cell biotransformation is more desirable than chemical synthesis. It is more eco-friendly and can increase the yield of desired products. In this study, we have found an enzymatic strategy of P450 enzymes for highly efficient synthesis of the 4-OH atorvastatin, which is an expensive commercial product, by using bacterial CYP102A1 peroxygenase activity with hydrogen peroxide without NADPH. We obtained a set of CYP102A1 mutants with high catalytic activity toward atorvastatin using enzyme library generation, high-throughput screening of highly active mutants, and enzymatic characterization of the mutants. In the hydrogen peroxide supported reactions, a mutant, with nine changed amino acid residues compared to a wild-type among tested mutants, showed the highest catalytic activity of atorvastatin 4-hydroxylation (1.8 min−1). This result shows that CYP102A1 can catalyze atorvastatin 4-hydroxylation by peroxide-dependent oxidation with high catalytic activity. The advantages of CYP102A1 peroxygenase activity over NADPH-supported monooxygenase activity are discussed. Taken together, we suggest that the P450 peroxygenase activity can be used to produce drugs’ metabolites for further studies of their efficacy and safety.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2018R1A4A1023882)
This publication has 29 references indexed in Scilit:
- Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in miceBrain Research Bulletin, 2019
- A decade of drug metabolite safety testing: industry and regulatory shared learningExpert Opinion on Drug Metabolism & Toxicology, 2017
- Simultaneous quantitation of atorvastatin and its two active metabolites in human plasma by liquid chromatography/(–) electrospray tandem mass spectrometryJournal of Pharmaceutical Analysis, 2014
- Effects of atorvastatin metabolites on induction of drug‐metabolizing enzymes and membrane transporters through human pregnane X receptorBritish Journal of Pharmacology, 2011
- Introduction: Human Metabolites in Safety Testing (MIST) IssueChemical Research in Toxicology, 2009
- Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatinXenobiotica, 2008
- Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular EventsDrugs, 2007
- AtorvastatinDrugs, 2007
- Understanding electron transport systems of Streptomyces cytochrome P450Biochemical Society Transactions, 2006
- Lipid-lowering drugsCellular and Molecular Life Sciences, 2006